Asset sale Announced
Grünenthal acquisition of Stivarga (regorafenib)
€375m consideration
Announced 21 Sep 2026
Advisers
Stivarga (regorafenib)
Target
Not disclosed
- Target
- Stivarga (regorafenib)
- Acquirer
- Grünenthal
- Seller
- Bayer AG
- Buyer based in
- Germany
- Seller based in
- Germany
- Sector
- Pharma
- Tags
- Pharma, Oncology
Similar deals
- Servier acquisition of Day One Biopharmaceuticals Mar 2026 · US$2.5bn · Biotech
- US WorldMeds acquisition of Orbus Therapeutics Oct 2026 · Pharma
- HealthCare Royalty acquisition of Modeyso commercial sales royalties Apr 2026 · Specialty finance and leasing
- LEO Pharma acquisition of global rights for MT-7117 (dersimelagon) Aug 2026 · US$435m · Pharma
- Galera Therapeutics and Obsidian Therapeutics merger Apr 2026 · US$414m · Biotech
Sources
- 21 Sep 2026 Freshfields advises Grünenthal on its acquisition of cancer treatment Stivarga from Bayer freshfields.com
- 21 Sep 2026 Press release (PR Newswire), Grünenthal acquires cancer treatment Stivarga® prnewswire.com